Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Evidence: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379

Computable Name:

version: 9; Last updated: 2025-12-11 20:35:21+0000; Language: en

Profile: NonComparativeEvidence

url: https://fevir.net/resources/Evidence/267232

identifier: FEvIR Object Identifier/267232, FEvIR Linking Identifier/NCT03421379-primaryOutcomeMeasure-0--OG000

name: NCT03421379_primaryOutcomeMeasure_0_OG000

title: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379

citeAs:

Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267232. Revised 2025-12-11. Available at: https://fevir.net/resources/Evidence/267232. Computable resource at: https://fevir.net/resources/Evidence/267232#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

description:

This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.

variableDefinition

description:

Glucagon Nasal Powder

note: ,

Outcome Measure Population Description: All randomized participant who completed both treatment visits and had evaluable treatment success data.

Outcome Measure Denominator Units: Participants

variableRole: Population

observed: A single dose of 3 mg glucagon nasal powder was administered intranasally (Identifier: ClinicalTrials.gov Outcome Measurement Group Id/OG000)

variableDefinition

variableRole: Outcome

observed: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration - (NCT03421379)

statistic

statisticType: Number (see protocol for details)

quantity: 100 percentage of participants

SampleSizes

-KnownDataCount
*68